Archive for the ‘Minding Your Business’ Category

Time To Clean Up Climate Science

By: Bradley Fikes —  November 28th, 2009

About four years ago, I wrote in the North County Times that the scientific case for global warming had been corroborated and blasted industry-funded skeptics as deceiving the public.

But since then I’ve had to confront evidence countering the widely held belief anthropogenic global warming really was settled science, as we are assured by non-scientist Al Gore..

A rival hypothesis, that the sun and cosmic rays influence cloud cover and hence temperatures, continues to generate peer-reviewed scientific papers. And the willingness of activists to embrace the most extreme, costly solutions, and to ignore less drastic interim steps, suggested by mainstream scientists, seems to be a political decision.

The recently leaked “Climategate” emails of climate scientists put many of the top researchers in an even less flattering light. The emails discuss keeping information from global warming skeptics, including what’s explicitly described as “dirty laundry.” Scientists discuss ways to ‘hide” data that suggest the climate is cooling. They discuss illegally deleting information subject to a Freedom of Information request. Doctoring records that don’t support global warming. Secretly colluding to thwart publication of skeptical science articles. And so on.

With some of these emails, it’s possible to squint your eyes just so, and pull out an innocent explanation, and that’s what some global warming believers have done. But it takes a real feat of mental gymnastics to do this for all of these emails. And some emails have no innocent explanation: The scientists explicitly admit they are hiding damaging data and trying to purge skeptics from the profession.

Climate science is in dire need of ethical housecleaning. The longer climate scientists delay and deny, the worse it will be for them, and for us.

(more…)

Rituxan Protects Beta Cells in Type I Diabetes

By: Bradley Fikes —  November 25th, 2009

Rituxan, the blockbuster cancer drug developed in San Diego, protects insulin-making cells in Type I diabetics, according to a new study published Wednesday in the New England Journal of Medicine.
The drug partially preserved the “beta cells” that produce insulin, said Dr. Mark D. Pescovitz of Indiana University, who led the study. The results, documented in patients over a one-year period, were encouraging enough that the patients will be studied for a second year.
“What this study showed is that a single treatment early in the course of diabetes had a positive effect,” Pescovitz said.
In Type I diabetes, the beta cells, found in the pancreas, are gradually destroyed. It’s an auto-immune disease, in which the body’s disease-fighting immune system turns against the body. About 5 to 10 percent of the 23.6 million Americans with diabetes have Type I, according to the American Diabetes Association. The rest have Type II diabetes, in which insulin becomes less effective.
Rituxan was developed by San Diego’s Idec Pharmaceuticals, a biotech company since merged into Biogen Idec, based in Cambridge, Mass. The drug being co-marketed by Biogen Idec along with Genentech, a South San Francisco-based subsidiary of the Swiss drug company Roche.
Rituxan attacks certain white blood cells called B cells that can go awry in various diseases. It was originally approved in 1997 to treat a form of non-Hodgkins lymphoma in which B cells become cancerous.
Since then, Rituxan has been approved to treat rheumatoid arthritis, another disease in which B cells have been implicated. It is now being studied as a treatment for chronic lymphocytic leukemia. Rituxan sales in the United States reached $670 million in the third quarter, compared to $655 million in the same quarter of 2008.
Pescovitz said the study began as a “proof of concept” that B cells were involved in the development of Type I diabetes.
“People did not believe that B cells were involved in the disease. They thought it was the T-cells,” Pescovitz said, referring to the other major type of white blood cell. “We showed if you get rid of the B cells, you can have an actual benefit. In future studies, we’ll now be able to optimize the treatment, perhaps giving additional courses of the drug.”

Javo Raises $4.1 Million Beans

By: Bradley Fikes —  November 23rd, 2009

Vista’s Javo Beverage Co., has raised $4.1 million in a private placement, the company announced in a Nov. 19 filing..
Javo makes coffee and tea for vending machines and other drink dispensers.

Stanley Crooke Gives Isis Shareholders A Pep Talk

By: Bradley Fikes —  November 23rd, 2009

Isis Pharmaceuticals has had a rough ride with its flagship drug for lowering cholesterol, mipomersen. The drug has shown effectiveness in reducing lipids in patients with a hereditary disease that causes extremely high levels of cholesterol. But safety concerns have sent the stock down.

Despite progress in Phase III clinical trials for mipomersen, Isis stock has fallen back from its late summer high of more than $18 to just over $11 a share, about where it started the year.

So Isis CEO Stanley T. Crook addressed shareholders today, thanking them for their support and saying the company is on the right track:

“We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.”

Crooke urged investors to listen to a replay of the mipomersen presentation conducted last week at a meeting of the American Heart Association.

Cal State San Marcos To Launch Biotech Lab Tech Program

By: Bradley Fikes —  November 23rd, 2009

Stepping up its focus on biotech, California State University San Marcos Extended Learning will begin offering a Biotechnology Laboratory Technician Certificate program.

According to CSUSM’s press release, “The program is specifically designed to provide program participants with the skills necessary to secure entry-level positions as biotechnology lab technicians or research assistants. Consisting of five classes (16 semester units), the part-time program is tailored to be completed within two semesters of study or approximately eight months.
The Biotechnology Laboratory Technician Certificate courses cover a range of topics deemed crucial in supplying a solid science foundation, supplemented by hands-on training in a laboratory setting. All courses are taught by CSUSM faculty from the Biology, Chemistry, Biochemistry, and Biotechnology departments, and will train students to be well-versed in cutting edge technologies and current market trends.”

For those who need a better scientific background to meet the program’s prerequisites, CSUSM offers a two-week “Biotechnology Boot Camp,” giving basic instruction in mathematics, chemistry and biology .

Federal funding is available for the program. Students who qualify as “Adult” or “Dislocated Workers” under the Workforce Investment Act (WIA) may be eligible to have all costs associated the program paid. The cost for the program is $$10,000. Without the Boot Camp, the cost of the program is $9,000.

To learn more about the program, go to www.csusm.edu/el or call 760-750-4020.

“The Project Success Method,” Clinton Padgett

By: Jeff Rowe —  November 17th, 2009

projectsuccess

San Diego-based project consultant Clinton Padgett offers a step-by-step how-to guide on managing a project from idea to completion.

How important is careful stewardship of a project? Consider an enterprise the reviewer was deeply engaged in three years ago —- a $10 million project to create an ultra-modern digital television studio. The project manager resisted all efforts to even create a spreadsheet so everyone involved could follow the acquisition and assembly of systems. He would smile, point to his head and say “it’s all in here.”

The folly of such a non-system became apparent after we had started broadcasting from the new studio and endured multiple equipment failures.
The CEO replaced the project manager and one of the first actions the new man took was to return $70,000 in equipment for which no use was evident. No question even a rudimentary system would have shown at least some of the items were not needed.
The book says 10,000 projects in 25 nations have been completely successfully using the Project Success Method.
Too bad our station was not one of them.
Besides reading the book, you can learn more about the the Project Success Method by going online to:
http://www.projectsuccess.com/

Water Legislation In A Nutshell

By: Bradley Fikes —  November 5th, 2009

For a quick overview of what California’s new water bill package means, I can do no better than point you to the blog post by Steve Doyle of Brookfield Homes.

There’s lots more devilishly intricate parts of this legislation, of course, but this overview lets you grok the purpose of each of the five bills.

Doyle helpfully included links to each bill, so you can read the full text. Would that I had found this post sooner! I just spent much of the morning tracking this down.

Homebuyer tax credit passes house

By: Eric Wolff —  November 5th, 2009

I don’t have the vote count yet, but the Mortgage Bankers Association says the House of Representatives passed the extension of the homebuyer tax credit . Now all the bill awaits is a presidential signature.

Update: The bill passed the House 403-12. The Senate passed the same bill yesterday 98-0.

Senate approves homebuyer credit extension

By: Eric Wolff —  November 4th, 2009

The U.S. Senate passed the bill containing the homebuyer tax credit expansion and extension unanimously on Wednesday, 98-0.

Update to the homebuyers extension: Delayed possibly till Thursday

By: Eric Wolff —  November 3rd, 2009

Looks like a possible extension of the homebuyer tax credit could potentially take another couple of days to come to a vote:

The following comes from Congress Daily, which has been quoted by Progress Illinois:

Monday’s vote cut off debate on the substitute amendment from Majority Leader Reid and Finance Chairman Max Baucus adding the tax breaks to the underlying unemployment insurance bill. Another cloture vote, this time on the amended bill, could occur as late as 11:40 tonight unless Republicans yield back time or agree to vitiate cloture. Even if cloture is invoked, Republicans would have up to another 30 hours to debate, pushing final passage off until Thursday.

So, there could be a vote tomorrow, or not until Thursday.